GlassScriptPhysician profile
Jennifer Collins
NPI 1942493440
$7,829.22
in general payments reported to CMS, 2019-2025
34 companies · $1,081 in 2025
The $1,081 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $589 · 2020: $1,367 · 2021: $2,401 · 2022: $660 · 2023: $875 · 2024: $856 · 2025: $1,081.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,790 · Consulting Fee: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,790.07 |
| Consulting Fee | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $1,710.55 | 2019-2023 | Grastek, Ragwitek, Odactra |
| Optinose US, INC. | $1,093.05 | 2019-2025 | |
| Genzyme Corporation | $866.05 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $627.56 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $620.60 | 2019-2025 | Nucala, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $440.06 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $300.01 | 2019-2023 | Dupixent |
| Grifols USA, LLC | $273.28 | 2019-2025 | Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $258.70 | 2020-2025 | Cuvitru, Hyqvia |
| Genentech USA, INC. | $209.61 | 2019-2025 | Xolair |
| Pharming Healthcare, INC. | $161.69 | 2024-2025 | Ruconest |
| Csl Behring | $152.73 | 2019-2025 | Hizentra |
| Novartis Pharmaceuticals Corporation | $133.36 | 2019-2025 | |
| Amgen INC. | $133.09 | 2020-2024 | Tezspire, Otezla |
| Kaleo, INC. | $129.10 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $90.55 | 2023-2025 | Adbry, Anzupgo |
| Phadia US INC. | $71.42 | 2020-2025 | Immunocap |
| Octapharma USA, INC. | $65.29 | 2020-2021 | |
| Incyte Corporation | $65.23 | 2022 | |
| Hikma Pharmaceuticals USA | $60.13 | 2023-2024 | Ryaltris |
| Ars Pharmaceuticals Operations, INC. | $49.71 | 2025 | Neffy |
| Organon LLC | $46.21 | 2025 | Vtama |
| Abbvie INC. | $37.95 | 2022-2025 | |
| Azurity Pharmaceuticals, INC. | $28.35 | 2025 | Alvesco |
| Intuitive Surgical, INC. | $26.12 | 2021 | |
| Aimmune Therapeutics, INC. | $24.09 | 2023 | |
| Biocryst US Sales Co., LLC | $23.78 | 2025 | Orladeyo |
| Adma Biomanufacturing LLC | $22.16 | 2023 | |
| Galderma Laboratories, L.P. | $21.71 | 2025 | Nemluvio |
| Sanofi-Aventis U.S. LLC | $21.23 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $17.12 | 2020 | |
| Shire North American Group INC | $17.03 | 2019 | |
| Circassia INC. | $16.00 | 2019 | |
| Dermavant Sciences, INC. | $15.70 | 2024 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.